drugset / Trial / NCT00410228

Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AHT956 in Healthy Subjects

NCT00410228 ↗

Phase 1 Completed 42 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety and tolerability of ascending single oral doses of AHT956 in healthy subjects

Timeline

Start
2006-06
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject AHT956 Unknown — —

Indications

No indication recorded.